Verici Dx plc (LON:VRCI – Get Free Report) reached a new 52-week low during mid-day trading on Wednesday . The stock traded as low as GBX 2.82 ($0.04) and last traded at GBX 3.08 ($0.04), with a volume of 433837 shares changing hands. The stock had previously closed at GBX 3.38 ($0.04).
Verici Dx Stock Up 2.6 %
The company has a debt-to-equity ratio of 4.65, a current ratio of 4.54 and a quick ratio of 8.49. The firm has a market capitalization of £7.15 million, a price-to-earnings ratio of -143.75 and a beta of 1.59. The business has a fifty day moving average price of GBX 5.15 and a two-hundred day moving average price of GBX 6.46.
About Verici Dx
Verici Dx plc develops prognostic and diagnostic tests for kidney transplant patients. Its lead products are Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection.
See Also
- Five stocks we like better than Verici Dx
- The How And Why of Investing in Oil Stocks
- 3 High-Yields Unfazed by the Election: Altria, Truist, Verizon
- What Are the FAANG Stocks and Are They Good Investments?
- Q3 Earnings Indicate On Holdings May Outperform Lululemon in 2024
- Stock Analyst Ratings and Canadian Analyst Ratings
- Cisco Systems Long-Term AI Play Turns a Corner: New Highs Likely
Receive News & Ratings for Verici Dx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verici Dx and related companies with MarketBeat.com's FREE daily email newsletter.
